博敏電子(603936.SH):減持期已屆滿 徐緩累計減持1.99%公司股份
格隆匯 6 月 23日丨博敏電子(603936.SH)公佈,截至本公告披露日,公司股東徐緩本次減持計劃的減持期間已屆滿,具體減持情況如下:在本次減持計劃實施期間(2019年12月26日至2020年1月3日),徐緩通過大宗交易方式累計減持6,282,000股,佔公司當時總股本的1.99%。2020年6月4日公司實施了2019年度利潤分配和資本公積金轉增股本方案,以資本公積金向全體股東每10股轉增4股,共轉增126,015,313股,本次分配後總股本為441,053,596股。截至本公告披露日,徐緩先生持有公司股份80,881,419股,佔目前公司總股本的18.34%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.